General Biologicals Corporation
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening… Read more
General Biologicals Corporation (4117) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.628x
Based on the latest financial reports, General Biologicals Corporation (4117) has a cash flow conversion efficiency ratio of -0.628x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-98.51 Million) by net assets (NT$156.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
General Biologicals Corporation - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how General Biologicals Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
General Biologicals Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of General Biologicals Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lixiang Education Holding Co Ltd
NASDAQ:LXEH
|
-0.808x |
|
FASING SA
WAR:FSG
|
0.000x |
|
Sidomulyo Selaras Tbk
JK:SDMU
|
0.006x |
|
Raubex
JSE:RBX
|
0.058x |
|
Bank Utica Ny Nonvtg
PINK:BKUTK
|
0.200x |
|
Jerusalem
TA:JBNK
|
0.111x |
|
Bodhi Tree Multimedia Limited
NSE:BTML
|
0.001x |
|
GREENROC MINING LS-001
F:3WF
|
N/A |
Annual Cash Flow Conversion Efficiency for General Biologicals Corporation (2019–2024)
The table below shows the annual cash flow conversion efficiency of General Biologicals Corporation from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$286.48 Million | NT$-116.11 Million | -0.405x | -189.19% |
| 2023-12-31 | NT$496.65 Million | NT$225.68 Million | 0.454x | +39.97% |
| 2022-12-31 | NT$693.07 Million | NT$225.01 Million | 0.325x | +511.98% |
| 2021-12-31 | NT$734.66 Million | NT$38.97 Million | 0.053x | -21.94% |
| 2020-12-31 | NT$687.74 Million | NT$46.74 Million | 0.068x | +378.81% |
| 2019-12-31 | NT$71.88 Million | NT$-1.75 Million | -0.024x | -- |